Onco'Zine - The International Cancer Network

ASCO 2026: Our Team’s Expert Insights from Onco'Zine, ADC Review, and More | Peter Hofland As the 2026 annual meeting of the American Society for Clinical Oncology (ASCO) approaches, our specialized oncology-focused team is gearing up to deliver comprehensive coverage from Chicago, Illinois. With more than 3,400 abstracts and late-breaking clinical trials, ASCO remains the world’s premi...

https://conta.cc/40zeStP

ADC Review and Onco'Zine - March 2026 Newsletter Email from Sunvalley Communication, LLC   March Newsletter   March 31, 2026 | 06   Diagnosing Colorectal Cancer: Debunking 5 Persistent Myths Many young adults mistakenly believe colorectal cancer is

https://conta.cc/4qvklNT

16th World ADC | 23rd - 26th February, 2026 | London, UK Email from Sunvalley Communication, LLC Europe’s definitive ADC event!     Greetings! Is the 16th World ADC London on your radar? Next month, 800+ ADC leaders from Europe, North America, and Asia will

https://conta.cc/4qSUtMh

Accelerate ADC Timelines & Mitigate Risks: Learn how Lonza's expertise simplifies Antibody-Drug Conjugate development. Antibody-drug conjugates (ADCs) are transforming therapeutic strategies—but their analytical development is anything but straightforward. Unlike small molecules or biologics, ADCs combine two modalities, creating unique challenges for scientists and developers.

New Staging Method for HPV-Positive Throat Cancer Gives Patients Better Information and a More Consistent Treatment

www.oncologydirectory.com

Join us at the London Biotechnology Show 2025, where innovation meets opportunity! https://conta.cc/3HB1cZ0

Secure Your Spot at the London Biotechnology Show 2025 Dear Reader, Join us at the London Biotechnology Show 2025, where innovation meets opportunity! Whether you are looking to explore the latest biotech breakthroughs with a complimentary Visitor Pass or gain premium access to industry leaders and exclusive content with a Delegate Pass, we have got the...

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399)

Telisotuzumab Vedotin (Emrelis®) Approved for Treatment of Patients Diagnosed with NSCLC with High c-Met protein Over-expression - Onco'Zine The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399; See Drug description and ADC Drugmap)*

AACR 2025: Conference Coverage Email from Sunvalley Communication, LLC You don't want to miss this.   Conference Coverage   May 13, 2025 | 05   Highlights from the Annual Meeting of the American Association for Cancer Research (AAC

A study by a team of researchers at the Karl Landsteiner University of Health Sciences in Austria (KL Krems) shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival.

The researchers found that that a higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy without increasing the risk of pneumonitis or severe lung inflammation. According to the researchers involved in the study, this is key finding of a recent study.

Click on the Link to read the Article

Study Shows High-Dose Radiotherapy to be Safe and Promising in Lung Cancer Treatment - Onco'Zine A study by a team of researchers at the Karl Landsteiner University of Health Sciences in Austria ((KL Krems) shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival.